0001493152-25-003984.txt : 20250128 0001493152-25-003984.hdr.sgml : 20250128 20250128161028 ACCESSION NUMBER: 0001493152-25-003984 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20250128 DATE AS OF CHANGE: 20250128 EFFECTIVENESS DATE: 20250128 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kairos Pharma, LTD. CENTRAL INDEX KEY: 0001962011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 462993314 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-536526 FILM NUMBER: 25564233 BUSINESS ADDRESS: STREET 1: 2355 WESTWOOD BLVD. #139 CITY: LOS ANGELES STATE: CA ZIP: 90064 BUSINESS PHONE: 818-404-5541 MAIL ADDRESS: STREET 1: 2355 WESTWOOD BLVD. #139 CITY: LOS ANGELES STATE: CA ZIP: 90064 D 1 primary_doc.xml X0708 D LIVE 0001962011 Kairos Pharma, LTD. 2355 WESTWOOD BLVD., #139 LOS ANGELES CA CALIFORNIA 90064 (310) 948-2356 DELAWARE NanoGB13, Inc None Corporation true John S. Yu 2355 Westwood Blvd., #139 Los Angeles CA CALIFORNIA 90064 Executive Officer Director Chairman, Chief Executive Officer, and Director Doug Samuelson 2355 Westwood Blvd., #139 Los Angeles CA CALIFORNIA 90064 Executive Officer Chief Financial Officer Ramachandran Murali 2355 Westwood Blvd., #139 Los Angeles CA CALIFORNIA 90064 Executive Officer Vice President of Research and Development Neil Bhowmick 2355 Westwood Blvd., #139 Los Angeles CA CALIFORNIA 90064 Executive Officer Chief Scientific Officer Hyun W. Bae 2355 Westwood Blvd., #139 Los Angeles CA CALIFORNIA 90064 Director Independent Director Hansoo Michael Keyoung 2355 Westwood Blvd., #139 Los Angeles CA CALIFORNIA 90064 Director Independent Director Rahul Singhvi 2355 Westwood Blvd., #139 Los Angeles CA CALIFORNIA 90064 Director Independent Director Pharmaceuticals Decline to Disclose 06b false 2025-01-16 false true true false 0 Boustead Securities, LLC 000141391 D. Boral Capital LLC 000103972 6 Venture, Ste. 395 Irvine CA CALIFORNIA 92618 NY NEW YORK false 8750000 3497500 5252500 Offering amount includes pre-funded warrants plus exercise price of warrants to purchase common stock. Total Remaining to be Sold consists of the aggregate exercise price of common stock underlying warrants. true 0 1 279800 0 Issuer paid placement agents cash compensation equal to 8% of the gross proceeds from the offering and issued warrants to purchase 175,000 shares of common stock. 0 false Kairos Pharma, LTD. /s/ John S. Yu John S. Yu Chief Executive Officer 2025-01-28